Chang Hyun Kim1, Jung Wook Huh2, Hyeong Rok Kim1, Young Jin Kim1. 1. Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Gwangju, Korea. 2. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
BACKGROUND AND AIMS: The CpG island methylator phenotype (CIMP) is found in approximately 30% of colorectal cancer (CRC) cases. However, the role of CIMP status in predicting oncologic outcomes in curatively resected CRC is still unclear. STUDY: Between January 2006 and December 2006, we retrospectively reviewed 157 consecutive patients who underwent curative surgery for CRC. Prognostic significance of CIMP status was evaluated using reverse transcriptase-polymerase chain reaction. RESULTS: CIMP-high (H) and CIMP-none/low (N/L) tumors were found in 50 cases (31.8%) and 107 cases (68.2%), respectively. CIMP-H tumors were significantly associated with female sex, colonic location, poorly/mucinous histologic type, higher T category, perineural invasion, and MSI-high status (P = 0.001). During a median of 64.5 months, tumor recurrence developed in 47 (29.9%) patients. The 5-year disease-free survival for CIMP-H and CIMP-N/L was 61.4% and 76.3% (P = 0.018). In addition, multivariate analysis showed that CIMP-H was also a significant prognostic factor (P = 0.042). When analysis was performed according to anatomical location, more marked survival differences were observed in patients with colon cancer (P = 0.026) than in patients with rectal cancer (P = 0.210). Similarly, the role of CIMP status as a prognostic indicator was more prominent in patients with stage I/II (P = 0.006) than in patients with stage III/IV CRC (P = 0.65). CONCLUSIONS: DNA methylation status can be considered as a useful predictor of survival after CRC surgery, particularly for patients with stage I/II disease or colon cancer.
BACKGROUND AND AIMS: The CpG island methylator phenotype (CIMP) is found in approximately 30% of colorectal cancer (CRC) cases. However, the role of CIMP status in predicting oncologic outcomes in curatively resected CRC is still unclear. STUDY: Between January 2006 and December 2006, we retrospectively reviewed 157 consecutive patients who underwent curative surgery for CRC. Prognostic significance of CIMP status was evaluated using reverse transcriptase-polymerase chain reaction. RESULTS: CIMP-high (H) and CIMP-none/low (N/L) tumors were found in 50 cases (31.8%) and 107 cases (68.2%), respectively. CIMP-H tumors were significantly associated with female sex, colonic location, poorly/mucinous histologic type, higher T category, perineural invasion, and MSI-high status (P = 0.001). During a median of 64.5 months, tumor recurrence developed in 47 (29.9%) patients. The 5-year disease-free survival for CIMP-H and CIMP-N/L was 61.4% and 76.3% (P = 0.018). In addition, multivariate analysis showed that CIMP-H was also a significant prognostic factor (P = 0.042). When analysis was performed according to anatomical location, more marked survival differences were observed in patients with colon cancer (P = 0.026) than in patients with rectal cancer (P = 0.210). Similarly, the role of CIMP status as a prognostic indicator was more prominent in patients with stage I/II (P = 0.006) than in patients with stage III/IV CRC (P = 0.65). CONCLUSIONS: DNA methylation status can be considered as a useful predictor of survival after CRC surgery, particularly for patients with stage I/II disease or colon cancer.
Authors: Rory F Kokelaar; Huw G Jones; Jeremy Williamson; Namor Williams; A Paul Griffiths; John Beynon; Gareth J Jenkins; Dean A Harris Journal: Cancer Biol Ther Date: 2018-01-19 Impact factor: 4.742
Authors: Martha L Slattery; Andrew J Pellatt; Frances Y Lee; Jennifer S Herrick; Wade S Samowitz; John R Stevens; Roger K Wolff; Lila E Mullany Journal: Oncotarget Date: 2017-08-03
Authors: Shailesh M Advani; Pragati Advani; Stacia M DeSantis; Derek Brown; Helena M VonVille; Michael Lam; Jonathan M Loree; Amir Mehrvarz Sarshekeh; Jan Bressler; David S Lopez; Carrie R Daniel; Michael D Swartz; Scott Kopetz Journal: Transl Oncol Date: 2018-07-30 Impact factor: 4.243
Authors: Shailesh Mahesh Advani; Pragati Shailesh Advani; Derek W Brown; Stacia M DeSantis; Krittiya Korphaisarn; Helena M VonVille; Jan Bressler; David S Lopez; Jennifer S Davis; Carrie R Daniel; Amir Mehrvarz Sarshekeh; Dejana Braithwaite; Michael D Swartz; Scott Kopetz Journal: BMC Cancer Date: 2019-10-17 Impact factor: 4.430
Authors: Amanda I Phipps; Elizabeth Alwers; Tabitha Harrison; Barbara Banbury; Hermann Brenner; Peter T Campbell; Jenny Chang-Claude; Daniel Buchanan; Andrew T Chan; Alton B Farris; Jane C Figueiredo; Steven Gallinger; Graham G Giles; Mark Jenkins; Roger L Milne; Polly A Newcomb; Martha L Slattery; Mingyang Song; Shuji Ogino; Syed H Zaidi; Michael Hoffmeister; Ulrike Peters Journal: Gastroenterology Date: 2020-02-20 Impact factor: 22.682